Cure GM1 is thankful for the collaboration of the GM1 community, other advocacy groups, biotechs, and academic groups. This page includes foundation-led publications and collaborative projects and publications with biotechs and academic groups. Cure GM1 or a person associated with Cure GM1 is credited as an author or there is an acknowledgement for our collaboration.
WORLD Symposium Abstracts and Posters
- World Symposium 2026
- World Symposium 2025
- World Symposium 2023: Development and validation of enzyme replacement therapy for GM1 gangliosidosis
- World Symposium 2020: Natural history of GM1 gangliosidosis mouse models generated by The Jackson Laboratory Rare and Orphan Disease Center
Patient-Led Initiatives
Qualitative Studies
- Burden of caregiving of individuals with GM1 and GM2 gangliosidoses in the United States: a qualitative study
- Motor function limitations and impacts among patients with GM1 AND GM2 gangliosidoses in the united states: A qualitative study
Newborn Screening
- Detection of GM1-gangliosidosis in newborn dried blood spots by enzyme activity and biomarker assays using tandem mass spectrometry
- Evaluation of Two Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Various Mucopolysaccharidoses and GM1 Gangliosidosis
- Endogenous, non-reducing end glycosaminoglycan biomarkers are superior to internal disaccharide glycosaminoglycan biomarkers for newborn screening of mucopolysaccharidoses and GM1 gangliosidosis
- Newborn screening for the full set of mucopolysaccharidoses in dried blood spots based on first-tier enzymatic assay followed by second-tier analysis of glycosaminoglycans
- ScreenPlus: A comprehensive, multi-disorder newborn screening program